Emerging Infectious Disease ISSN: 1080-6059

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha*

, Erik J. Dasbach*, and Ralph P. Insinga*

Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Figure 7

Sensitivity analysis. A) Incidence of cervical cancer due to human papillomavirus (HPV) 16/18 infection among girls and women >12 years of age with 50% coverage. B) Incidence of cervical cancer due to HPV 16/18 infection among girls and women >12 years of age with 90% coverage.

Figure 7. Sensitivity analysis. A) Incidence of cervical cancer due to human papillomavirus (HPV) 16/18 infection among girls and women >12 years of age with 50% coverage. B) Incidence of cervical cancer due to HPV 16/18 infection among girls and women >12 years of age with 90% coverage.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.